The concept was so tantalizing. Medicine within the GLP-1 class, which incorporates Wegovy and Ozempic, have proved miraculous in treating weight loss and other diseases. And a few researchers hoped that the medicine may additionally assist with a few of the most troublesome illnesses to deal with — these of the mind, like Parkinson’s.
However now, at the very least for Parkinson’s, that hope appears dimmed. A rigorous research that randomly assigned Parkinson’s sufferers to take exenatide, a relative of Ozempic, confirmed completely no profit or slowing of the course of the degenerative illness after 96 weeks.
And there have been no impact on affected person signs, no impact on mind scans, no subgroup that confirmed any profit. Regardless of how the researchers sliced the information the outcomes have been the identical.
The study, printed Tuesday in The Lancet, is unhealthy information for the half million People who’ve been recognized with Parkinson’s illness. Signs embrace tremors, stiffness and problem with stability. Sufferers additionally could develop dementia. Remedies, together with medicines and deep mind stimulation, may also help with signs. However no therapy has been proven to gradual the illness’s progress.
“It’s vastly disappointing,” mentioned Dr. Thomas Foltynie of College School London, who led the trial. “We have been anticipating we’d come by means of and we’d get a optimistic consequence.”
Parkinson’s consultants shared his sentiment.
“It is a sobering second,” mentioned Dr. Michael S. Okun, a Parkinson’s illness knowledgeable on the College of Florida and the nationwide medical adviser for the Parkinson’s Basis. “It is a rather well completed research and it got here up empty-handed.”
The discovering could have implications for researchers who’re asking if the newer GLP-1 medicine could help slow the course of Alzheimer’s or may stop the illness.
The brand new research concerned 194 individuals with Parkinson’s illness handled at six analysis hospitals within the U.Ok. The sufferers have been randomly assigned to inject themselves as soon as every week for 96 weeks with exenatide, a sort 2 diabetes therapy made by AstraZeneca and offered below the model title Byetta, or with a placebo. The trial was funded by Britain’s Nationwide Institute for Well being and Care Analysis with help for substudies from the charity Treatment Parkinson’s and the Van Andel Institute.
The drug is in the identical class as Ozempic and Wegovy and, like them, lowers blood sugar ranges. All are so-called GLP-1 receptor agonists, generally known as GLP-1s. Exenatide will not be as highly effective in eliciting weight reduction because the newer medicine, however consultants say there is no such thing as a cause to consider that the more moderen medicine would carry out otherwise in research of mind illness.
The outcomes, researchers mentioned, are particularly disappointing as a result of there have been solutions that GLP-1 medicine may assist Parkinson’s sufferers.
GLP-1 drugs protected neurons from harm in laboratory research and in a study with rats given a mind harm like that in Parkinson’s illness.
It started to look that the outcomes may additionally apply to sufferers.
“Folks began digging into claims databases,” Dr. Okun mentioned, explaining that researchers had examined giant databases displaying medicine that individuals took and their diagnoses. The researchers requested if sufferers who had taken GLP-1s may be much less more likely to get Parkinson’s or, if that they had it, would have a illness that progressed extra slowly.
The outcomes have been promising.
They appeared at epidemiological studies. They discovered that individuals with diabetes who took GLP-1s have been much less more likely to have Parkinson’s.
Then two small studies suggested that exenatide might slow the progression of some Parkinson’s signs over a 12 months’s time.
Persevering with the hints of progress, a bigger however nonetheless preliminary research, published last year within the New England Journal of Drugs, discovered {that a} GLP-1 that’s now not available on the market — lixisenatide — appeared to slightly slow progress of the illness over a 12 months.
Dr. Okun, on the time, mentioned that the consequence was “nibbling on the edges of illness modification.”
“What we had final 12 months was a one-year trial and a small sign,” mentioned Dr. David Standaert, a Parkinson’s researcher on the College of Alabama at Birmingham. “What would occur in case you went longer? Properly, that is longer and there’s simply not a lot right here.”
The issue with finding out GLP-1s in Parkinson’s illness, Dr. Standaert mentioned, is that what exenatide is meant to be doing within the mind will not be clear.
“I wouldn’t do one other research like this except you study what’s the goal,” Dr. Standaert mentioned. “What’s the biochemistry you are attempting to alter within the mind? How do these medicine work, anyway?”
